Answers are grounded in this paper and cite their sources.
MET exon 14 skipping mutation ( MET ∆ex14) is present about 3% of non-small cell lung cancers (NSCLCs). NSCLC patients with MET ∆ex14 are characterized by an average age of over 70 years at diagnosis, a smoking history and a higher frequency in pleomorphic carcinoma and adenosquamous cell carcinoma than in adenocarcinoma. It has also been reported that NSCLCs with MET ∆ex14 often have codriver alterations such as EGFR amplification (6– 28%), FGFR1 alterations (5– 17%), KRAS alterations (∼ 8%), BRAF alterations (∼ 21%), or PIK3CA mutation/amplification (∼ 14%). In 2020, the approval of two MET-tyrosine kinase inhibitors (TKIs), capmatinib and tepotinib, for NSCLCs carrying MET ∆ex14 dawned a new era for MET-targeted therapy. These drugs yielded progression-free survival of 5.4− 12.4 months in clinical trials; however, it has also been reported that one-third to half of patients show inherent resistance to MET-TKIs. In addition, the emergence of acquired resistance to MET-TKIs is inevitable. In this review, we summarize the clinical and molecular characteristics of NSCLCs with MET ∆ex14, the efficacy and safety of capmatinib and tepotinib, the inherent and acquired resistance mechanisms to MET-TKIs, and new treatment strategies for NSCLCs with MET ∆ex14 in the near future.
No takes yet. Share an insight, caveat, or question.
Fujino et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: